

Annual Index 2011: Subject

Academic detailing

Back to school: quality improvement through academic detailing [Patel B] 7:455

Access to healthcare

Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access [Lieberman JN, Girdish C] 2:95

When more is almost always better [Gellad WF] 2:99

Accountable care organizations

ACO payment model a potential “game changer,” but will it improve outcomes? [Vogenberg FR] 7:450

Are ACOs the answer to high-value healthcare? [Yeung W, et al] 7:441

Moving beyond Medicare’s ACOs to accountable care [Karamchedu M, et al] 4:204

We must all engage in the diabetes challenge: a lifelong journey, with no silver bullet [Collins CE] 6:386

Adherence

Degree of adherence in chronic diseases inversely correlates with healthcare costs [AMCP highlights] 3:166

When information is insufficient: inspiring patients for medication adherence and the role of social support networking [Hennessey M, Heryer JW] 1:10

Anticoagulation therapy

Anticoagulation bridging therapy after total hip or knee replacement: a missed opportunity? [Collins CE] 4:248

Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a US health plan: real-world observations and implications [Baser O, et al] 4:240

Antidepressants

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78

Efficacy and cost-effectiveness: escitalopram versus citalopram [Mitchell M] 2:87

Antipsychotics

Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications [Riordan HJ, et al] 5:292

Asthma medications

Medicaid spending on asthma medications [Amick B] 3:149

Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 [Chiu S, et al] 3:140

Benefit design

Benefit management considerations for BPH medications: single agent or combination therapy? [Mitchell M] 3:161

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

From Asheville to Hickory: transforming our “sick care” system into a true “health care” model [Garrett DG] 6:336

Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Impact of value-based insurance design on medication utilization and costs in a large retail employer [AMCP highlights] 3:163

Medical claims data can inform coverage decisions in managed care health plans [Murphy MF] 6:361

Perspectives in value-based insurance design for patients with diabetes: assessment and application [Arevalo JD] 1:27

Re-engineering the healthcare continuum: implementing value-based insurance design to improve diabetes management [Taylor SR] 1:32

Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature [Shenolikar R, et al] 7:465

Systematic health management: the time has come to do the right thing for each person [Rideout JJ] 3:152

Benign prostatic hyperplasia medications

Benefit management considerations for BPH medications: single agent or combination therapy? [Mitchell M] 3:161

Economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia [Naslund M, et al] 3:155

Cancer care

Drug shortages the “new” old problem: people are (finally) talking [Helwick C] 7:483

Era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy [Stricker S] 6:387

Cardiometabolic health

Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications [Riordan HJ, et al] 5:292

Cutting-edge data presented at ADA 2011

highlight the diabetes–cardiovascular disease link [Kuznar W] 6:412

In search of stakeholder collaboration to stem the cardiometabolic epidemic [Buffery D] 5:270

Lipid management in patients with type 2 diabetes [Daniel MJ] 5:312

Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271

Time is now to promote aggressive lipid management to prevent macrovascular complications in patients with type 2 diabetes [Owens GM] 5:321

We must all engage in the diabetes challenge: a lifelong journey, with no silver bullet [Collins CE] 6:386

Chronic diseases

Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications [Riordan HJ, et al] 5:292

Call to action: responding to the future forecasting of chronic disease in America [Page RL, et al] 5:280

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78

Cutting-edge data presented at ADA 2011 highlight the diabetes–cardiovascular disease link [Kuznar W] 6:412

Degree of adherence in chronic diseases inversely correlates with healthcare costs [AMCP highlights] 3:166

Drugs in phase 3 clinical trials for type 2 diabetes [Goodman A] 6:410

Emerging therapies for type 1 and type 2 diabetes [ADA highlights] 4:251

Employers’ obesity initiatives in the workplace: a wakeup call for health plans [Lednar WM] 5:278

Five steps healthcare leaders can take to address childhood obesity [Lovejoy JJ] 1:50

From Asheville to Hickory: transforming our “sick care” system into a true “health care” model [Garrett DG] 6:336

Health plans must “COPE” with chronic diseases [Owens GM] 1:15

Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Lipid management in patients with type 2 diabetes [Daniel MJ] 5:312

- Medicaid spending on asthma medications [Amick B] 3:149
- New therapies with novel mechanisms of action are urgently needed for type 2 diabetes [Felicetta JV] 5:311
- Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271
- Perspectives in value-based insurance design for patients with diabetes: assessment and application [Arevalo JD] 1:27
- Postapproval development options in COPD: a case study in value-based healthcare systems [Murphy ME, et al] 1:19
- Potential cost-savings using a treatment algorithm for problem bleeding episodes in patients with hemophilia and inhibitors [Lima HA] 4:228
- Prevention efforts before disease strikes the key to a healthy population of young adults [Kenney JT] 5:287
- Re-engineering the healthcare continuum: implementing value-based insurance design to improve diabetes management [Taylor SR] 1:32
- Review of strategies to enhance outcomes for patients with type 2 diabetes: payers' perspective [Greenapple R] 6:377
- Time is now to promote aggressive lipid management to prevent macrovascular complications in patients with type 2 diabetes [Owens GM] 5:321
- We must all engage in the diabetes challenge: a lifelong journey, with no silver bullet [Collins CE] 6:386
- Collaborative care**
- Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab [Johnson R, Freeman EN] 1:39
- Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications [Riordan HJ, et al] 5:292
- Collaborative approach to drug selection, driven by clinical outcomes excellence [Rangaves D] 3:179
- Complexities of treating mental illness [Kaddis AA] 5:301
- Economic and clinical value of integrating a clinical pharmacist into the care management team [AMCP highlights] 3:163
- From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172
- In search of stakeholder collaboration to stem the cardiometabolic epidemic [Buffery D] 5:270
- Comparative effectiveness research**
- Anticoagulation bridging therapy after total hip or knee replacement: a missed opportunity? [Collins CE] 4:248
- Comparative effectiveness research in the United States: a catalyst for innovation [Ali R, et al] 2:68
- Compliance** *See Adherence*
- Coordinated care**
- Systematic health management: the time has come to do the right thing for each person [Rideout J] 3:152
- Costs** *See Health economics*
- Cost-effectiveness**
- Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78
- Efficacy and cost-effectiveness: escitalopram versus citalopram [Mitchell M] 2:87
- Cost trends**
- Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab [Johnson R, Freeman EN] 1:39
- Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343
- Keeping a lid on health plan costs, one patient at a time [Miller R] 6:350
- Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature [Shenolikar R, et al] 7:465
- Diabetes management**
- Current therapies and emerging drugs in the pipeline for type 2 diabetes [Nguyen QT, et al] 5:303
- Cutting-edge data presented at ADA 2011 highlight the diabetes–cardiovascular disease link [Kuznar W] 6:412
- Drugs in phase 3 clinical trials for type 2 diabetes [Goodman A] 6:410
- Emerging therapies for type 1 and type 2 diabetes [ADA highlights] 4:251
- From Asheville to Hickory: transforming our “sick care” system into a true “health care” model [Garrett DG] 6:336
- Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343
- Impact of treatment by NCQA-certified physicians on diabetes-related outcomes [Pinsky B, et al] 7:429
- Lipid management in patients with type 2 diabetes [Daniel MJ] 5:312
- New therapies with novel mechanisms of action are urgently needed for type 2 diabetes [Felicetta JV] 5:311
- Perspectives in value-based insurance design for patients with diabetes: assessment and application [Arevalo JD] 1:27
- Re-engineering the healthcare continuum: implementing value-based insurance design to improve diabetes management [Taylor SR] 1:32
- Review of strategies to enhance outcomes for patients with type 2 diabetes: payers' perspective [Greenapple R] 6:377
- Time is now to promote aggressive lipid management to prevent macrovascular complications in patients with type 2 diabetes [Owens GM] 5:321
- We must all engage in the diabetes challenge: a lifelong journey, with no silver bullet [Collins CE] 6:386
- Drug abuse**
- Just say no [Kaddis AA] 2:113
- Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs [Hahn KL] 2:107
- Drug development**
- Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab [Johnson R, Freeman EN] 1:39
- Current therapies and emerging drugs in the pipeline for type 2 diabetes [Nguyen QT, et al] 5:303
- Current trends in the pharmaceutical pipeline: key players to watch, few surprises [AMCP highlights] 3:164
- Drugs in phase 3 clinical trials for type 2 diabetes [Goodman A] 6:410
- Emerging therapies for type 1 and type 2 diabetes [ADA highlights] 4:251
- Era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy [Stricker S] 6:387
- New therapies with novel mechanisms of action are urgently needed for type 2 diabetes [Felicetta JV] 5:311
- Postapproval development options in COPD: a case study in value-based healthcare systems [Murphy ME, et al] 1:19
- Drug manufacturers**
- Drug shortages the “new” old problem: people are (finally) talking [Helwick C] 7:483
- Drug shortages**
- Drug shortages the “new” old problem: people are (finally) talking [Helwick C] 7:483
- Employers**
- Employers' obesity initiatives in the workplace: a wakeup call for health plans [Lednar WM] 5:278
- Impact of value-based insurance design on medication utilization and costs in a large retail employer [AMCP highlights] 3:163
- Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343
- Keeping a lid on health plan costs, one patient at a time [Miller R] 6:350

Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271

Formulary

Collaborative approach to drug selection, driven by clinical outcomes excellence [Rangaves D] 3:179

Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature [Shenolikar R, et al] 7:465

Generics

First generic ARB approval draws a wave of comparative studies [Buffery D] 1:48

New economic analysis zeroes in on low generic utilization and waste in Medicaid [Buffery D] 2:118

Health economics

Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab [Johnson R, Freeman EN] 1:39

Building your automated bundled payment for an episode-of-care initiative [Moeller D] 6:403

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78

Current therapies and emerging drugs in the pipeline for type 2 diabetes [Nguyen QT, et al] 5:303

Degree of adherence in chronic diseases inversely correlates with healthcare costs [AMCP highlights] 3:166

Economic and clinical value of integrating a clinical pharmacist into the care management team [AMCP highlights] 3:163

Economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia [Naslund M, et al] 3:155

Efficacy and cost-effectiveness: escitalopram versus citalopram [Mitchell M] 2:87

From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172

Health as a sustainability strategy: we need a healthcare system focused on keeping people healthy rather than adding layers to the already too long, fragmented supply chain [Colombi AM] 4:215

Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353

Hickory Project: controlling healthcare costs

and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Impact of value-based insurance design on medication utilization and costs in a large retail employer [AMCP highlights] 3:163

Just say no [Kaddis AA] 2:113

Keeping a lid on health plan costs, one patient at a time [Miller R] 6:350

Managing utilization by exception [Zubiller M] 4:233

Medicaid spending on asthma medications [Amick B] 3:149

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors [Bonnet P, et al] 4:219

New strategies needed to combat increasing costs and optimize use of infused therapies [Radzin RF] 1:45

Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271

Potential cost-savings using a treatment algorithm for problem bleeding episodes in patients with hemophilia and inhibitors [Lima HA] 4:228

Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs [Hahn KL] 2:107

Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 [Chiu S, et al] 3:140

We need more research on true value-based benefit design that will improve outcomes and control costs [Owens GM] 7:473

Health information exchange

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

Health plans See Payers

Healthcare reform

ACO payment model a potential “game changer,” but will it improve outcomes? [Vogenberg FR] 7:450

Adapting to market changes: beyond healthcare reform [Vogenberg FR] 6:368

Are ACOs the answer to high-value healthcare? [Yeung W, et al] 7:441

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

Health as a sustainability strategy: we need a healthcare system focused on keeping people healthy rather than adding layers to the already too long, fragmented supply chain [Colombi AM] 4:215

Moving beyond Medicare’s ACOs to accountable care [Karamchedu M, et al] 4:204

Patient-centered medical home: an essential destination on the road to reform [Adamson M] 2:122

Systematic health management: the time has come to do the right thing for each person [Rideout JJ] 3:152

Heart disease

Call to action: responding to the future forecasting of chronic disease in America [Page RL, et al] 5:280

Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353

Medical claims data can inform coverage decisions in managed care health plans [Murphy MF] 6:361

Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271

Prevention efforts before disease strikes the key to a healthy population of young adults [Kenney JT] 5:287

Hemophilia

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors [Bonnet P, et al] 4:219

Potential cost-savings using a treatment algorithm for problem bleeding episodes in patients with hemophilia and inhibitors [Lima HA] 4:228

Hickory project

From Asheville to Hickory: transforming our “sick care” system into a true “health care” model [Garrett DG] 6:336

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Keeping a lid on health plan costs, one patient at a time [Miller R] 6:350

Hospitals

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172

Humana pilot project

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

Industry trends

ACO payment model a potential “game

changer,” but will it improve outcomes? [Vogenberg FR] 7:450

Back to school: quality improvement through academic detailing [Patel B] 7:455

Building your automated bundled payment for an episode-of-care initiative [Moeller D] 6:403

Managing utilization by exception [Zubiller M] 4:233

Drug shortages the “new” old problem: people are (finally) talking [Helwick C] 7:483

Patient-centered medical home: an essential destination on the road to reform [Adamson M] 2:122

Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access [Lieberman JN, Girdish C] 2:95

When more is almost always better [Gellad WF] 2:99

Innovation

Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab [Johnson R, Freeman EN] 1:39

Building your automated bundled payment for an episode-of-care initiative [Moeller D] 6:403

Comparative effectiveness research in the United States: a catalyst for innovation [Ali R, et al] 2:68

Employers’ obesity initiatives in the workplace: a wakeup call for health plans [Lednar WM] 5:278

From Asheville to Hickory: transforming our “sick care” system into a true “health care” model [Garrett DG] 6:336

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

New strategies needed to combat increasing costs and optimize use of infused therapies [Radzin RF] 1:45

Insurance premiums See **Payers**

Lipid management

Lipid management in patients with type 2 diabetes [Daniel MJ] 5:312

Time is now to promote aggressive lipid management to prevent macrovascular complications in patients with type 2 diabetes [Owens GM] 5:321

Medicaid

CMS invites feedback on the proposed accountable care organizations rules [Buffery D] 2:120

Do medication therapy management programs achieve their goals? [AMCP highlights] 3:166

Medicaid spending on asthma medications [Amick B] 3:149

New economic analysis zeroes in on low generic utilization and waste in Medicaid [Buffery D] 2:118

Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 [Chiu S, et al] 3:140

Medical education

Back to school: quality improvement through academic detailing [Patel B] 7:455

When information is insufficient: inspiring patients for medication adherence and the role of social support networking [Hennessey M, Heryer JW] 1:10

Medical home

Patient-centered medical home: an essential destination on the road to reform [Adamson M] 2:122

Systematic health management: the time has come to do the right thing for each person [Rideout JJ] 3:152

Medicare

Are ACOs the answer to high-value health-care? [Yeung W, et al] 7:441

CMS invites feedback on the proposed accountable care organizations rules [Buffery D] 2:120

Do medication therapy management programs achieve their goals? [AMCP highlights] 3:166

Moving beyond Medicare’s ACOs to accountable care [Karamchedu M, et al] 4:204

Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature [Shenolikar R, et al] 7:465

Medication cost management

From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172

Mental health

Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications [Riordan HJ, et al] 5:292

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78

Complexities of treating mental illness [Kaddis AA] 5:301

National Committee for Quality Assurance Certification

Impact of treatment by NCQA-certified physicians on diabetes-related outcomes [Pinsky B, et al] 7:429

Obesity

Employers’ obesity initiatives in the workplace: a wakeup call for health plans [Lednar WM] 5:278

Five steps healthcare leaders can take to address childhood obesity [Lovejoy JJ] 1:50

Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271

Outcomes

ACO payment model a potential “game changer,” but will it improve outcomes? [Vogenberg FR] 7:450

Anticoagulation bridging therapy after total hip or knee replacement: a missed opportunity? [Collins CE] 4:248

Collaborative approach to drug selection, driven by clinical outcomes excellence [Rangaves D] 3:179

From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Impact of treatment by NCQA-certified physicians on diabetes-related outcomes [Pinsky B, et al] 7:429

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors [Bonnet P, et al] 4:219

Review of strategies to enhance outcomes for patients with type 2 diabetes: payers’ perspective [Greenapple R] 6:377

We need more research on true value-based benefit design that will improve outcomes and control costs [Owens GM] 7:473

Payers

ACO payment model a potential “game changer,” but will it improve outcomes? [Vogenberg FR] 7:450

Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a US health plan: real-world observations and implications [Baser O, et al] 4:240

Building your automated bundled payment for an episode-of-care initiative [Moeller D] 6:403

Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care [Tzeel A, et al] 4:207

Collaborative approach to drug selection, driven by clinical outcomes excellence [Rangaves D] 3:179

Employers’ obesity initiatives in the workplace: a wakeup call for health plans [Lednar WM] 5:278

Health plans must “COPE” with chronic diseases [Owens GM] 1:15

Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343

Keeping a lid on health plan costs, one patient at a time [Miller R] 6:350

Medical claims data can inform coverage

decisions in managed care health plans [Murphy MF] 6:361
Perspectives in value-based insurance design for patients with diabetes: assessment and application [Arevalo JD] 1:27
Review of strategies to enhance outcomes for patients with type 2 diabetes: payers' perspective [Greenapple R] 6:377
Systematic health management: the time has come to do the right thing for each person [Rideout JJ] 3:152

Personalized medicine

Era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy [Stricker S] 6:387

Pharmacists

Drug shortages the "new" old problem: people are (finally) talking [Helwick C] 7:483
Economic and clinical value of integrating a clinical pharmacist into the care management team [AMCP highlights] 3:163
From A to Z: medication cost-management strategies for disproportionate share hospitals [Henry A, et al] 3:172
Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access [Lieberman JN, Girdish C] 2:95
When more is almost always better [Gellad WF] 2:99

Pharmacoeconomics

Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353
Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 [Chiu S, et al] 3:140

Pipeline See Drug development

Policy

ACO payment model a potential "game changer," but will it improve outcomes? [Vogenberg FR] 7:450
Drug shortages the "new" old problem: people are (finally) talking [Helwick C] 7:483
From Asheville to Hickory: transforming our "sick care" system into a true "health care" model [Garrett DG] 6:336
Health as a sustainability strategy: we need a healthcare system focused on keeping people healthy rather than adding layers to the already too long, fragmented supply chain [Colombi AM] 4:215
See also Medicaid; Medicare

Postapproval

Postapproval development options in COPD:

a case study in value-based healthcare systems [Murphy MF, et al] 1:19

Prevention

Prevention efforts before disease strikes the key to a healthy population of young adults [Kenney JT] 5:287

Providers

ACO payment model a potential "game changer," but will it improve outcomes? [Vogenberg FR] 7:450
Back to school: quality improvement through academic detailing [Patel B] 7:455
Impact of treatment by NCQA-certified physicians on diabetes-related outcomes [Pinsky B] 7:429
What certification really means for physician quality [Gellad WF] 7:438

Quality of care

Back to school: quality improvement through academic detailing [Patel B] 7:455
From Asheville to Hickory: transforming our "sick care" system into a true "health care" model [Garrett DG] 6:336
Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project Model [Bunting BA, et al] 6:343
What certification really means for physician quality [Gellad WF] 7:438

Real-world data

Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a US health plan: real-world observations and implications [Baser O, et al] 4:240

Research

Comparative effectiveness research in the United States: a catalyst for innovation [Ali R, et al] 2:68
Medical claims data can inform coverage decisions in managed care health plans [Murphy MF] 6:361
We need more research on true value-based benefit design that will improve outcomes and control costs [Owens GM] 7:473

Retail pharmacy

Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access [Lieberman JN, Girdish C] 2:95
When more is almost always better [Gellad WF] 2:99

Social networking

When information is insufficient: inspiring patients for medication adherence and the role of social support networking [Hennessey M, Heryer JW] 1:10

Technology

Building your automated bundled payment for an episode-of-care initiative [Moeller D] 6:403

Utilization

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram [Wu EQ, et al] 2:78
Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting [Kempf J, et al] 6:353
Impact of value-based insurance design on medication utilization and costs in a large retail employer [AMCP highlights] 3:163
Managing utilization by exception [Zubiller M] 4:233
New economic analysis zeroes in on low generic utilization and waste in Medicaid [Buffery D] 2:118
New strategies needed to combat increasing costs and optimize use of infused therapies [Radzin RF] 1:45
Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care [Colombi AM, Wood GC] 5:271
Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 [Chiu S, et al] 3:140

Value-based healthcare

Are ACOs the answer to high-value healthcare? [Yeung W, et al] 7:441
Economic and clinical value of integrating a clinical pharmacist into the care management team [AMCP highlights] 3:163
Impact of a value-based insurance design on medication utilization and costs in a large retail employer [AMCP highlights] 3:163
Managing utilization by exception [Zubiller M] 4:233
Perspectives in value-based insurance design for patients with diabetes: assessment and application [Arevalo JD] 1:27
Postapproval development options in COPD: a case study in value-based healthcare systems [Murphy MF, et al] 1:19
Re-engineering the healthcare continuum: implementing value-based insurance design to improve diabetes management [Taylor SR] 1:32
Systematic health management: the time has come to do the right thing for each person [Rideout JJ] 3:152
We need more research on true value-based benefit design that will improve outcomes and control costs [Owens GM] 7:473

Annual Index 2011: Authors

- Adamson M. Patient-centered medical home: an essential destination on the road to reform 2:122
- Ali R, Hanger M, Carino T. Comparative effectiveness research in the United States: a catalyst for innovation 2:68
- Amick B. Medicaid spending on asthma medications [Stakeholder Perspective] 3:149
- Arevalo JD. Perspectives in value-based insurance design for patients with diabetes: assessment and application 1:27
- Baser O, Supina D, Sengupta N, Wang L. Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a US health plan: real-world observations and implications 4:240
- Bonnet P, Gringeri A, Gomperts E, Leissing CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors 4:219
- Buffery D. First generic ARB approval draws a wave of comparative studies 1:48; New economic analysis zeroes in on low generic utilization and waste in Medicaid 2:118; CMS invites feedback on the proposed accountable care organizations rules 2:120; In search of stakeholder collaboration to stem the cardiometabolic epidemic 5:270
- Bunting BA, Lee G, Knowles G, Lee C, Allen P. Hickory Project: controlling healthcare costs and improving outcomes for diabetes using the Asheville Project model 6:343
- Chiu SF, Kelton CML, Guo JJ, Wigle PR, Lin AC, Szeinbach SL. Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010 3:140
- Collins CE. Anticoagulation bridging therapy after total hip or knee replacement: a missed opportunity? [Stakeholder Perspective] 4:248; We must all engage in the diabetes challenge: a lifelong journey, with no silver bullet [Stakeholder Perspective] 6:386
- Colombi AM. Health as a sustainability strategy: we need a healthcare system focused on keeping people healthy rather than adding layers to the already too long, fragmented supply chain [Stakeholder Perspective] 4:215
- Colombi AM, Wood GC. Obesity in the workplace: impact on cardiovascular disease, cost, and utilization of care 5:271
- Daniel MJ. Lipid management in patients with type 2 diabetes 5:312
- Felicetta JV. New therapies with novel mechanisms of action are urgently needed for type 2 diabetes [Stakeholder Perspective] 5:311
- Garrett DG. From Asheville to Hickory: transforming our "sick care" system into a true "health care" model [Editorial] 6:336
- Gellad WF. What certification really means for physician quality [Stakeholder Perspective] 7:438; When more is almost always better [Stakeholder Perspective] 2:99
- Goodman A. Drugs in phase 3 clinical trials for type 2 diabetes 6:410
- Greenapple R. Review of strategies to enhance outcomes for patients with type 2 diabetes: payers' perspective 6:377
- Hahn KL. Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs 2:107
- Helwick C. Drug shortages the "new" old problem: people are (finally) talking 7:483
- Hennessey M, Heryer JW. When information is insufficient: inspiring patients for medication adherence and the role of social support networking 1:10
- Henry A, Erowele GI, Ndefo UA, Milton-Brown J, Anassi E, Green W, Alvidrez A, Okpara AU. From A to Z: medication cost-management strategies for disproportionate share hospitals 3:172
- Johnson R, Freeman EN. Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab 1:39
- Kaddis AA. Just say no [Stakeholder Perspective] 2:113; Complexities of treating mental illness [Stakeholder Perspective] 5:301
- Karamchedu M, Muppalla S, Capobianco R. Moving beyond Medicare's ACOs to accountable care [Perspective] 4:204
- Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting 6:353
- Kenney JT. Prevention efforts before disease strikes the key to a healthy population of young adults [Stakeholder Perspective] 5:287
- Lednar WM. Employers' obesity initiatives in the workplace: a wakeup call for health plans [Stakeholder Perspective] 5:278
- Lieberman JN, Girdish C. Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access 2:95
- Lima HA. Potential cost-savings using a treatment algorithm for problem bleeding episodes in patients with hemophilia and inhibitors [Stakeholder Perspective] 4:228
- Lovejoy J. Five steps healthcare leaders can take to address childhood obesity [Perspective] 1:50
- Miller R. Keeping a lid on health plan costs, one patient at a time [Stakeholder Perspective] 6:350
- Mitchell M. Efficacy and cost-effectiveness: escitalopram versus citalopram [Stakeholder Perspective] 2:87; Benefit management considerations for BPH medications: single agent or combination therapy? [Stakeholder Perspective] 3:161
- Moeller D. Building your automated bundled payment for an episode-of-care initiative 6:403
- Murphy MF. Medical claims data can inform coverage decisions in managed care health plans [Stakeholder Perspective] 6:361
- Murphy MF, Antonini P, Lai ZV. Postapproval development options in COPD: a case-study in value-based healthcare systems 1:19
- Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia 3:155
- Nguyen QT, Thomas KT, Lyons KB, Nguyen LD, Plodkowski RA. Current therapies and emerging drugs in the pipeline for type 2 diabetes 5:303
- Owens GM. Health plans must "COPE" with chronic diseases [Stakeholder Perspective] 1:15; Time is now to promote aggressive lipid management to prevent macrovascular complications in patients with type 2 diabetes 5:321; We need more research on true value-based benefit design that will improve outcomes and control costs [Stakeholder Perspective] 7:473
- Page RL, Ghushchyan V, Nair K. Call to action: responding to the future forecasting of chronic disease in America 5:280
- Patel B. Back to school: quality improvement through academic detailing 7:455
- Pinsky B, Harnett J, Paulose-Ram R, Mardekian J, Samant N, Nair KV. Impact of treatment by NCQA-certified physicians on diabetes-related outcomes 7:429
- Radzin RF. New strategies needed to combat increasing costs and optimize use of infused therapies [Stakeholder Perspective] 1:45

- Rangaves D. Collaborative approach to drug selection, driven by clinical outcomes excellence [Stakeholder Perspective] 3:179
- Rideout J. Systematic health management: the time has come to do the right thing for each person [Perspective] 3:152
- Riordan HJ, Antonini P, Murphy ME. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications 5:292
- Shenolikar R, Bruno AS, Eaddy M, Cantrell C. Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature 7:465
- Stricker S. Era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy [Perspective] 6:387
- Taylor SR. Re-engineering the healthcare continuum: implementing value-based insurance design to improve diabetes management [Stakeholder Perspective] 1:32
- Tzeel A, Lawnicki V, Pemble KR. Business case for payer support of a community-based health information exchange: a Humana pilot evaluating its effectiveness in cost control for plan members seeking emergency department care 4:207
- Vogenberg FR. Adapting to market changes: beyond healthcare reform [Perspective] 6:368; ACO payment model a potential “game changer,” but will it improve outcomes? [Stakeholder Perspective] 7:450
- Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram 2:78
- Yeung W, Burns H, Loiacono D. Are ACOs the answer to high-value healthcare? 7:441
- Zubiller M. Managing utilization by exception 4:233